Nephrocare Health Services IPO: Should you apply?

Summary: Nephrocare Health Services, India’s largest chain of dialysis clinics, is set to go public on December 10, 2025. We breakdown its pros, cons and financial performance to help you understand if its IPO is worth subscribing to.

Nephrocare Health Services, a dialysis services provider, will open its IPO (initial public offering) on December 10, 2025 and close on December 12, 2025. The issue size, totalling Rs 871 crore, comprises a fresh issue of Rs 353 crore while the remaining Rs 518 crore will be raised through an offer for sale (OFS).

Below is a detailed analysis of the company’s strengths, weaknesses, financials and past valuations to help you make an informed investment decision.

What the company does

Nephrocare Health Services is India’s largest dialysis provider, far ahead of its nearest competitor, with the highest number of patients, clinics, cities served, treatments performed, revenue and EBITDA. In FY25, it treated over 29,000 patients and performed nearly 2.9 million dialysis sessions, or about 10 per cent of all dialysis treatments in the country. The company is also the largest dialysis provider in Asia and the fifth largest globally by treatments performed.

Nephrocare is the only Indian dialysis chain to scale internationally, operating 519 clinics across India and overseas markets such as the Philippines, Uzbekistan and Nepal. Its network spans 288 cities and 21 states, with more than three-fourths of its clinics located in tier II and III towns, giving it deep regional reach.

Track record and valuation

When it comes to financials, Nephrocare Health Services seems to have fared impressively for the most part. During FY23-25, its revenue surged by nearly 32 per cent every year, while EBIT (earnings before interest and taxes) leapt by 641 per cent.

At the upper end of the price band (Rs 460), Nephrocare Health Services’ stock is expected to be valued at over 69 times its FY25 earnings and 4.3 times its book value. By contrast, its peers trade at a P/E and P/B of 54 times and 12.3 times, respectively.

The good

Below are some of the key strengths of Nephrocare Health Services.

#1 Biggest dialysis chain in India and Asia

Nephrocare is India’s largest dialysis chain and the biggest in Asia, with a scale more than four times that of its next-largest domestic competitor. It holds over half of the organised Indian market by both treatments and revenue, and ranks fifth globally based on treatments performed in FY25. The company offers a full suite of dialysis services — from centre-based and home dialysis to holiday and mobile dialysis — ensuring broad accessibility. Treatment volumes have grown rapidly, supported by a rising base of dialysis machines.

Nephrocare is also the only Indian player to expand internationally, with more than 30 per cent of FY25 revenue coming from overseas operations. Its network spans 288 cities across India, with a heavy concentration in tier II and III locations, and ranks among the top three dialysis chains in the Philippines.

#2 Asset-light and cost-efficient operating model

Nephrocare has scaled rapidly from a single clinic in 2010 to 519 clinics across India and international markets, supported by a mix of greenfield, brownfield and PPP (public-private partnership) models. Its asset-light strategy keeps capital costs low, with over half its clinics operating on revenue-sharing arrangements, enabling efficient expansion and strong unit economics.

A cluster-based approach helps the company deepen its presence in high-demand regions, especially in tier II and III towns, which contribute more than 70 per cent of revenue. Centralised procurement and standardised clinic formats further strengthen cost efficiency. This widespread network ensures easy access to dialysis care and has helped Nephrocare consolidate its leadership, serving about 10 per cent of India’s dialysis patients in FY25.

The bad

Here are some of the risks faced by Nephrocare Health Services.

#1 Dependence on private hospitals for revenues

A meaningful share of Nephrocare Health Services’ revenue comes from captive clinics or dialysis centres operated inside private hospitals under contractual agreements, with the former accounting for 37 per cent and 43 per cent of the company’s operating revenue for the six months ended September 2025 and FY25, respectively. This reliance creates contractual risk: if hospitals terminate, renegotiate or choose not to renew these arrangements, the company’s revenue and operations could be materially affected.

#2 Interest and exchange-rate related risks

Nephrocare faces exposure to interest rate and currency fluctuations, which can affect its financing costs and overall financial performance. Part of its operations is funded through debt, including borrowings linked to variable interest rates. Any rise in rates would increase interest expenses and strain profitability. While the company may refinance on reset dates, there is no certainty that it can secure favourable terms. If refinancing options fall short or market rates move unfavourably, its cost of debt could rise further, impacting results.

#3 PPP contracts constitute a sizable portion of the company’s revenue

Nephrocare also depends on public–private partnership (PPP) contracts, which contribute a sizable portion to its core revenue. These agreements, awarded through competitive bidding, carry renewal and bidding risks. Failure to qualify for or win future tenders could affect growth, revenue visibility and cash flows. As of September 2025, the company operated PPP clinics across multiple Indian states — including Karnataka, Andhra Pradesh, Bihar and Uttarakhand — as well as four clinics in Uzbekistan under a government tender.

Where will the IPO proceeds go?

Of the fresh issue size of Rs 353 crore, Nephrocare Health Services aims to utilise over Rs 129 crore towards the establishment of new dialysis clinics across the country. It will also use around Rs 136 crore for the repayment of its debt.

The remaining funds will be utilised for general corporate purposes.

So, should you subscribe to the Nephrocare Health Services IPO?

At Value Research, we advise investors to approach IPOs with caution. The excitement of listing day often fades quickly, and many new stocks struggle to hold their momentum — a setback for anyone chasing fast returns. For those serious about long-term wealth creation, IPOs are seldom the right starting point.

Sustained compounding usually comes from mature businesses that have survived multiple market cycles and proven their strength over the years. Value Research Stock Advisor helps you find such companies — those with strong fundamentals, consistent track records and the ability to keep compounding long after the IPO frenzy has passed.

Subscribe to Stock Advisor today

Also read: Park Medi World IPO: The good and the bad